FEATURED NEWS

• HDA Statement on Proposed HHS Rule on Prescription Drug Importation

  December 18, 2019

  The Healthcare Distribution Alliance (HDA) released the following statement regarding the Department of Health and Human Services' (HHS) proposed rule permitting prescription drug importation.

• HDA Statement on Senate Judiciary Committee Hearing on Mitigating the Opioid Crisis

  December 17, 2019

  The Healthcare Distribution Alliance (HDA) released the following statement following the organization’s testimony before the Senate Judiciary Committee on “Tackling the Opioid Crisis: A Whole-of-Government Approach.”

• Analysis of Specialty Distributors Reveals Continued Growth

  December 13, 2019

  A new analysis published by the HDA Research Foundation indicates that oncology drugs, autoimmune and HIV therapeutics fueled specialty pharmaceutical segment growth in 2018. The 2019 Specialty Pharmaceutical Distribution: Facts, Figures and Trends indicates that oncology therapeutics account for most specialty distributor sales at 48.4 percent.

• Pharmaceutical Sales Through Primary Distributors Reach $493 Billion

  December 6, 2019

  In 2018, sales through pharmaceutical distributors increased by 6.7 percent, reaching $492.54 billion, according to a new report by the HDA Research Foundation. The 90th Edition HDA Factbook: The Facts, Figures and Trends in Healthcare (2019–2020) also notes that chain drug stores were the largest customer base for pharmaceutical wholesalers — accounting for 44.6 percent of all sales, a slight increase from 2017. Distributor margins, however, continued a four-year slide, though they showed increases in efficiency.

• HDA Statement on Proposed DEA Regulations

  October 28, 2019

  In response to the Drug Enforcement Administration’s (DEA) proposed regulations related to the review and monitoring of annual production quotas, the Healthcare Distribution Alliance (HDA) released the following statement.